Celyad OncologyCLYYF 28 Market Cap is $12.71 Mil as of Jun. 26, 2026. GuruFocus rates CLYYF with a GF Score™ of 28/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,431 Biotechnology companies, Celyad Oncology ranks worse than 81.9% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Celyad Oncology's share price for the quarter that ended in Dec. 2025 was $0.15. Celyad Oncology's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 44.76 Mil. Therefore, Celyad Oncology's market cap for the quarter that ended in Dec. 2025 was $6.71 Mil.
Celyad Oncology's quarterly market cap
increased
from Dec. 2024 ($10.15 Mil) to Jun. 2025 ($20.71 Mil) but then
declined
from Jun. 2025 ($20.71 Mil) to Dec. 2025 ($6.71 Mil).
Celyad Oncology's annual market cap
declined
from Dec. 2023 ($17.89 Mil) to Dec. 2024 ($10.15 Mil) and
declined
from Dec. 2024 ($10.15 Mil) to Dec. 2025 ($6.71 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Celyad Oncology's Enterprise Value for Today is $10.77 Mil.
Celyad Oncology (OTCPK:CLYYF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Celyad Oncology Market Cap Related Terms
Celyad Oncology Market Cap Historical Data
* Premium members only.
The historical data trend for Celyad Oncology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Celyad Oncology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's Market Cap distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Celyad Oncology's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celyad Oncology (CLYYF) has a Market Cap of $12.71 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Celyad Oncology and its competitors. According to the industry distribution chart, Celyad Oncology ranks #1172 out of 1431 companies in the Biotechnology industry, placing it in the top 81.9%.
Is Celyad Oncology's Market Cap too high?
Celyad Oncology's current Market Cap is $12.71 Mil. The Biotechnology industry median Market Cap is 113.83. Celyad Oncology's value of $12.71 Mil is 88.8% below this industry median. Based on the distribution chart, Celyad Oncology ranks #1172 out of 1431 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celyad Oncology has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #1172 out of 1431 companies for Market Cap. This places Celyad Oncology in the lower half of its industry. The industry median Market Cap is 113.83. Celyad Oncology's value of $12.71 Mil is 88.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celyad Oncology's current Market Cap of $12.71 Mil is 88.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Celyad Oncology and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celyad Oncology's current Market Cap is $12.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.25 — trading 66.7% above its estimated fair value. The current Market Cap is $12.71 Mil and 88.8% below the Biotechnology industry median of 113.83. Celyad Oncology's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current Market Cap is $12.71 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celyad Oncology (CLYYF) Overvalued in 2026?
Based on GuruFocus' analysis, Celyad Oncology stock appears to be overvalued.
The current stock price of $0.25 is trading 66.7% above its estimated GF Value™ of $0.15.
GuruFocus considers Celyad Oncology to be Significantly Overvalued.
Key valuation signals for CLYYF:
Market Cap: $12.71 Mil
GF Value™: $0.15 vs. price of $0.25 (66.7% above fair value)
Industry Position: 88.8% below the Biotechnology median (#1172 of 1431)
No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
28GF Score
Get the complete analysis for CLYYF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
